For the Inventor, By the Inventor

Enter assignee name

Sankyo Company, Limited

Calculating rank

USPTO Granted Patents = 613

% Expired Patents = 12.2

CIPO Patents = 2

EPO Patents = 4

Trademarks = 10

Forward Citations = 5,739

Loading Chart...

Loading Chart...

751 inventors (with patents filed for the assignee):

Takao Yoshioka (53 out of 53 patents)

Tomoyuki Kurumada (35 out of 36 patents)

Hiroyuki Koike (32 out of 41 patents)

4. Hiroaki Yanagisawa (30 out of 38 patents)

5. Hiroyoshi Horikoshi (30 out of 30 patents)

6. Takashi Fujita (30 out of 165 patents)

7. Toshihiko Fujiwara (25 out of 28 patents)

8. Koichi Fujimoto (23 out of 23 patents)

9. Syoji Morimura (23 out of 23 patents)

10. Atsusuke Terada (22 out of 22 patents)

11. Yoshio Iizuka (21 out of 73 patents)

12. Koichi Kojima (21 out of 23 patents)

13. Sadao Ishihara (20 out of 20 patents)

14. Yasuhiro Morisawa (19 out of 19 patents)

15. Akira Terahara (19 out of 19 patents)

Core Competencies:

Antibody

Cancer Treatment

Diabetes Remedy

Pharmaceutical Composition

Amino Alcohol Compounds

Oligonucleotides

Tumor Specific Antigen

Lipid Ameliorant

Antibacterial Compound

Osteoclastogenesis Inhibitory Factor

Benzimidazole Derivatives

Crystalline Forms

613 patents: Sort by Forward Citations

1. 8980272 - Antibody targeting osteoclast-associated protein (2015-03-17),

2. 8967721 - Headrest support device (2015-03-03),

3. 8572933 - Method for manufacturing soft capsule and apparatus for manufacturing the same (2013-11-05),

4. 8263349 - Antibody specific for a mammalian sphingosine kinase type 2 isoform protein and methods of use thereof (2012-09-11),

5. 8106079 - Intermediate of 6-substituted-1-methyl-1-H-benzimidazole derivative and method for producing same (2012-01-31),

6. 8067396 - Amino alcohol compounds or phosphonic acid derivatives thereof (2011-11-29),

7. 7994152 - Method of treating a cancer by administering A 2',5′-oligoadenylate analog (2011-08-09),

8. 7943584 - Medicinal composition containing diabetes remedy (2011-05-17),

9. 7910617 - Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound (2011-03-22),

10. 7906639 - Oligonucleotides having a 2'-O,4′-C-ethylene nucleotide in the third position of the 3′-end (2011-03-15),

11. 7863243 - Anti-tumor agent (2011-01-04),

12. 7855056 - Antibody against tumor specific antigen as target (2010-12-21),

13. 7829580 - Cyclic amine derivative having heteroaryl ring (2010-11-09),

14. 7816552 - Intermediate of 6-substituted 1-methyl-1-H-benzimidazole derivative and method for producing same (2010-10-19),

15. 7811556 - Polymeric modifiers and pharmaceutical compositions (2010-10-12),

Company Overview

Sankyo Company, Limited, headquartered in Tokyo, Japan, specializes in the development and manufacturing of pharmaceutical compositions with a focus on innovative treatments for cancer and diabetes. The company is engaged in advanced research in areas such as antibody therapies, tumor-specific antigens, and oligonucleotides, aiming to enhance therapeutic efficacy and patient outcomes. With a commitment to addressing critical health challenges, Sankyo leverages its expertise in amino alcohol compounds and lipid ameliorants to drive progress in the pharmaceutical industry.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

613 Patents

#159 in Tokyo

#328 in Japan

#1,598 in the World

Sankyo Company, Limited

Forward Citations = 5,739

751 inventors:

Takao Yoshioka (53 out of 53 patents)

Tomoyuki Kurumada (35 out of 36 patents)

Hiroyuki Koike (32 out of 41 patents)

4. Hiroaki Yanagisawa (30 out of 38 patents)

5. Hiroyoshi Horikoshi (30 out of 30 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sankyo Company, Limited. Retrieved from https://idiyas.com/company/sankyo-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…